Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes
Oxidative stress is implicated in the pathogenesis of multiple sclerosis (MS). Defence against oxidative damage is mediated by antioxidants. Peroxiredoxin V (PRDX V) is an intracellular anti-oxidant enzyme with peroxynitrite reductase activity. It is increased during inflammation, when free radical...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2007-09, Vol.13 (8), p.955-961 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 961 |
|---|---|
| container_issue | 8 |
| container_start_page | 955 |
| container_title | Multiple sclerosis |
| container_volume | 13 |
| creator | Holley, J.E. Newcombe, J. Winyard, P.G. Gutowski, N.J. |
| description | Oxidative stress is implicated in the pathogenesis of multiple sclerosis (MS). Defence against oxidative damage is mediated by antioxidants. Peroxiredoxin V (PRDX V) is an intracellular anti-oxidant enzyme with peroxynitrite reductase activity. It is increased during inflammation, when free radical production intensifies, and is protective in an animal model of brain injury. However, little is known about PRDX V expression in the human brain. We investigated PRDX V expression in white matter from normal human brain (n = 5) and MS patients (n = 18), using immunohistochemistry and immunoblotting. A global increase in PRDX V was evident in MS normal-appearing white matter (NAWM) but the most striking increase was in astrocytes in MS lesions. PRDX V- positive hypertrophic reactive astrocytes were seen in acute lesions where inflammation was present. Yet surprisingly, in chronic lesions (CL), where inflammation has abated and a glial scar formed, there was strong PRDX V staining of post-reactive, scar astrocytes. Furthermore, immunoblotting analysis of tissue from two MS cases confirmed a substantial increase in PRDX V expression in CL compared with NAWM from the same individual. This might indicate ongoing oxidative stress despite the absence of histologically defined inflammation. Further investigations of this phenomenon will be of interest for therapeutic targeting. Multiple Sclerosis 2007; 13: 955—961. http://msj.sagepub.com |
| doi_str_mv | 10.1177/1352458507078064 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68316462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458507078064</sage_id><sourcerecordid>68316462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-fe15396d71da7309481f9f3e62990fb4b09ca650c05e9db1424d7ce4810c21273</originalsourceid><addsrcrecordid>eNqFkctLxDAQxoMorq-7JymC3qqTR5vGm4gvWFDwcS1pOpVKH2umBfe_N2UXFgTxMkn4fjPJl4-xYw4XnGt9yWUiVJIloEFnkKottseV1jEYDdthH-R40mdsn-gTALSWyS6bcZ0KqaXZYy_P6Pvv2mMZahe9R6G0YzPUiwYjck1QqaaoQar7jq6ixUS2dWe7IcLvcKJJiIplZGnwvVsOSIdsp7IN4dF6PWBvd7evNw_x_On-8eZ6HjuVmSGukCfSpKXmpdUSjMp4ZSqJqTAGqkIVYJxNE3CQoCkLroQqtcOAgRNcaHnAzldzF77_GpGGvK3JYdPYDvuR8jSTPFXB6X-ggFQkkkMAT3-Bn_3ou2AiFzzLFDcyCxCsIBf-hjxW-cLXrfXLnEM-xZL_jiW0nKznjkWL5aZhnUMAztaAJWebytvO1bThDBhpzGQ5XnFkP3DzuD8v_gF7J6EI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218841938</pqid></control><display><type>article</type><title>Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Holley, J.E. ; Newcombe, J. ; Winyard, P.G. ; Gutowski, N.J.</creator><creatorcontrib>Holley, J.E. ; Newcombe, J. ; Winyard, P.G. ; Gutowski, N.J.</creatorcontrib><description>Oxidative stress is implicated in the pathogenesis of multiple sclerosis (MS). Defence against oxidative damage is mediated by antioxidants. Peroxiredoxin V (PRDX V) is an intracellular anti-oxidant enzyme with peroxynitrite reductase activity. It is increased during inflammation, when free radical production intensifies, and is protective in an animal model of brain injury. However, little is known about PRDX V expression in the human brain. We investigated PRDX V expression in white matter from normal human brain (n = 5) and MS patients (n = 18), using immunohistochemistry and immunoblotting. A global increase in PRDX V was evident in MS normal-appearing white matter (NAWM) but the most striking increase was in astrocytes in MS lesions. PRDX V- positive hypertrophic reactive astrocytes were seen in acute lesions where inflammation was present. Yet surprisingly, in chronic lesions (CL), where inflammation has abated and a glial scar formed, there was strong PRDX V staining of post-reactive, scar astrocytes. Furthermore, immunoblotting analysis of tissue from two MS cases confirmed a substantial increase in PRDX V expression in CL compared with NAWM from the same individual. This might indicate ongoing oxidative stress despite the absence of histologically defined inflammation. Further investigations of this phenomenon will be of interest for therapeutic targeting. Multiple Sclerosis 2007; 13: 955—961. http://msj.sagepub.com</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458507078064</identifier><identifier>PMID: 17623739</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Astrocytes - pathology ; Biological and medical sciences ; Brain - cytology ; Brain - pathology ; Cadaver ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Gene Expression Regulation ; Humans ; Immunoblotting ; Immunohistochemistry ; Immunomodulators ; Medical sciences ; Multiple Sclerosis - pathology ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Peroxiredoxins - metabolism ; Pharmacology. Drug treatments ; Reference Values</subject><ispartof>Multiple sclerosis, 2007-09, Vol.13 (8), p.955-961</ispartof><rights>2008 INIST-CNRS</rights><rights>SAGE Publications © Sep 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-fe15396d71da7309481f9f3e62990fb4b09ca650c05e9db1424d7ce4810c21273</citedby><cites>FETCH-LOGICAL-c489t-fe15396d71da7309481f9f3e62990fb4b09ca650c05e9db1424d7ce4810c21273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458507078064$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458507078064$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19093997$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17623739$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holley, J.E.</creatorcontrib><creatorcontrib>Newcombe, J.</creatorcontrib><creatorcontrib>Winyard, P.G.</creatorcontrib><creatorcontrib>Gutowski, N.J.</creatorcontrib><title>Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Oxidative stress is implicated in the pathogenesis of multiple sclerosis (MS). Defence against oxidative damage is mediated by antioxidants. Peroxiredoxin V (PRDX V) is an intracellular anti-oxidant enzyme with peroxynitrite reductase activity. It is increased during inflammation, when free radical production intensifies, and is protective in an animal model of brain injury. However, little is known about PRDX V expression in the human brain. We investigated PRDX V expression in white matter from normal human brain (n = 5) and MS patients (n = 18), using immunohistochemistry and immunoblotting. A global increase in PRDX V was evident in MS normal-appearing white matter (NAWM) but the most striking increase was in astrocytes in MS lesions. PRDX V- positive hypertrophic reactive astrocytes were seen in acute lesions where inflammation was present. Yet surprisingly, in chronic lesions (CL), where inflammation has abated and a glial scar formed, there was strong PRDX V staining of post-reactive, scar astrocytes. Furthermore, immunoblotting analysis of tissue from two MS cases confirmed a substantial increase in PRDX V expression in CL compared with NAWM from the same individual. This might indicate ongoing oxidative stress despite the absence of histologically defined inflammation. Further investigations of this phenomenon will be of interest for therapeutic targeting. Multiple Sclerosis 2007; 13: 955—961. http://msj.sagepub.com</description><subject>Astrocytes - pathology</subject><subject>Biological and medical sciences</subject><subject>Brain - cytology</subject><subject>Brain - pathology</subject><subject>Cadaver</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Gene Expression Regulation</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>Immunohistochemistry</subject><subject>Immunomodulators</subject><subject>Medical sciences</subject><subject>Multiple Sclerosis - pathology</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Peroxiredoxins - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Reference Values</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkctLxDAQxoMorq-7JymC3qqTR5vGm4gvWFDwcS1pOpVKH2umBfe_N2UXFgTxMkn4fjPJl4-xYw4XnGt9yWUiVJIloEFnkKottseV1jEYDdthH-R40mdsn-gTALSWyS6bcZ0KqaXZYy_P6Pvv2mMZahe9R6G0YzPUiwYjck1QqaaoQar7jq6ixUS2dWe7IcLvcKJJiIplZGnwvVsOSIdsp7IN4dF6PWBvd7evNw_x_On-8eZ6HjuVmSGukCfSpKXmpdUSjMp4ZSqJqTAGqkIVYJxNE3CQoCkLroQqtcOAgRNcaHnAzldzF77_GpGGvK3JYdPYDvuR8jSTPFXB6X-ggFQkkkMAT3-Bn_3ou2AiFzzLFDcyCxCsIBf-hjxW-cLXrfXLnEM-xZL_jiW0nKznjkWL5aZhnUMAztaAJWebytvO1bThDBhpzGQ5XnFkP3DzuD8v_gF7J6EI</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>Holley, J.E.</creator><creator>Newcombe, J.</creator><creator>Winyard, P.G.</creator><creator>Gutowski, N.J.</creator><general>SAGE Publications</general><general>Arnold</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20070901</creationdate><title>Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes</title><author>Holley, J.E. ; Newcombe, J. ; Winyard, P.G. ; Gutowski, N.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-fe15396d71da7309481f9f3e62990fb4b09ca650c05e9db1424d7ce4810c21273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Astrocytes - pathology</topic><topic>Biological and medical sciences</topic><topic>Brain - cytology</topic><topic>Brain - pathology</topic><topic>Cadaver</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Gene Expression Regulation</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>Immunohistochemistry</topic><topic>Immunomodulators</topic><topic>Medical sciences</topic><topic>Multiple Sclerosis - pathology</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Peroxiredoxins - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Reference Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holley, J.E.</creatorcontrib><creatorcontrib>Newcombe, J.</creatorcontrib><creatorcontrib>Winyard, P.G.</creatorcontrib><creatorcontrib>Gutowski, N.J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holley, J.E.</au><au>Newcombe, J.</au><au>Winyard, P.G.</au><au>Gutowski, N.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>13</volume><issue>8</issue><spage>955</spage><epage>961</epage><pages>955-961</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>Oxidative stress is implicated in the pathogenesis of multiple sclerosis (MS). Defence against oxidative damage is mediated by antioxidants. Peroxiredoxin V (PRDX V) is an intracellular anti-oxidant enzyme with peroxynitrite reductase activity. It is increased during inflammation, when free radical production intensifies, and is protective in an animal model of brain injury. However, little is known about PRDX V expression in the human brain. We investigated PRDX V expression in white matter from normal human brain (n = 5) and MS patients (n = 18), using immunohistochemistry and immunoblotting. A global increase in PRDX V was evident in MS normal-appearing white matter (NAWM) but the most striking increase was in astrocytes in MS lesions. PRDX V- positive hypertrophic reactive astrocytes were seen in acute lesions where inflammation was present. Yet surprisingly, in chronic lesions (CL), where inflammation has abated and a glial scar formed, there was strong PRDX V staining of post-reactive, scar astrocytes. Furthermore, immunoblotting analysis of tissue from two MS cases confirmed a substantial increase in PRDX V expression in CL compared with NAWM from the same individual. This might indicate ongoing oxidative stress despite the absence of histologically defined inflammation. Further investigations of this phenomenon will be of interest for therapeutic targeting. Multiple Sclerosis 2007; 13: 955—961. http://msj.sagepub.com</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>17623739</pmid><doi>10.1177/1352458507078064</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2007-09, Vol.13 (8), p.955-961 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68316462 |
| source | Access via SAGE; MEDLINE |
| subjects | Astrocytes - pathology Biological and medical sciences Brain - cytology Brain - pathology Cadaver Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Gene Expression Regulation Humans Immunoblotting Immunohistochemistry Immunomodulators Medical sciences Multiple Sclerosis - pathology Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology Peroxiredoxins - metabolism Pharmacology. Drug treatments Reference Values |
| title | Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T03%3A07%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peroxiredoxin%20V%20in%20multiple%20sclerosis%20lesions:%20predominant%20expression%20by%20astrocytes&rft.jtitle=Multiple%20sclerosis&rft.au=Holley,%20J.E.&rft.date=2007-09-01&rft.volume=13&rft.issue=8&rft.spage=955&rft.epage=961&rft.pages=955-961&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1177/1352458507078064&rft_dat=%3Cproquest_cross%3E68316462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218841938&rft_id=info:pmid/17623739&rft_sage_id=10.1177_1352458507078064&rfr_iscdi=true |